As the COVID-19 public health emergency’s continuous coverage requirement ends and states redetermine eligibility for Medicaid and Children’s Health Insurance Program enrollees, the Department of Health and Human Services’ Office for Civil Rights April 5 reminded state health officials of their obligations under federal civil right laws to provide meaningful language access for individuals with limited English proficiency and ensure effective communication with individuals with disabilities. 

“OCR is deeply committed to helping states ensure that eligible individuals with LEP and individuals with disabilities are provided with meaningful language access and effective communication to ensure they do not experience an otherwise unnecessary lapse in coverage,” said OCR Director Melanie Fontes Rainer. “OCR is available to provide technical assistance to states and encourages agencies to take proactive steps to ensure meaningful access and effective communication by developing, reviewing, and/or updating plans for the provision of these vital services, including how people will be informed of the availability of language assistance services and auxiliary aids and services.”
 

Related News Articles

Headline
The AHA today participated in a panel discussion during a conference hosted by The Capitol Forum on the impact of insurer vertical integration. Molly Smith,…
Headline
The Department of Health and Human Services Office of Inspector General yesterday issued an alert warning of marketing schemes by certain Medicare Advantage…
Headline
In this conversation, Terry Scoggin, CEO of Titus Regional Medical Center, discusses how the organization designed a system of care to ensure that every…
Headline
The Congressional Budget Office Dec. 5 informed Congress that 2.2 million consumers would lose their health insurance in 2026 if enhanced premium subsidies are…
Headline
A $2.8 billion settlement from Blue Cross Blue Shield to health care providers resolving a 12-year antitrust lawsuit received preliminary approval yesterday…
Headline
The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex…